Help Pharmacy: Company Overview & Business Model

What Is Help Pharmacy and How Does It Operate?

Help Pharmacy is a large-scale compounding pharmacy headquartered in Houston, Texas. It compounds and dispenses prescription medications that are not commercially available in their exact formulation, dose, or delivery form. The company operates under two separate FDA regulatory designations, which gives it broader reach than a typical neighborhood compounding shop.

503A vs. 503B: Why the Distinction Matters

The FDA distinguishes two compounding pathways under the Drug Quality and Security Act of 2013.

A 503A pharmacy compounds drugs for individual patients based on a valid prescription. Products are not subject to FDA's new drug approval process but must meet U.S. Pharmacopeia (USP) standards and state pharmacy board rules. Help's 503A arm serves patients with prescriptions from their own physicians or telehealth providers.

A 503B outsourcing facility can produce large batches without patient-specific prescriptions and may sell to hospitals and clinics. The FDA inspects 503B facilities on a risk-based schedule similar to drug manufacturers. Help is registered as a 503B outsourcing facility, meaning its sterile compounding operations face a meaningfully higher level of federal scrutiny than a 503A-only pharmacy. The FDA publishes its current list of registered outsourcing facilities, and Help appears on that list [1].

This dual status is not universal among compounding pharmacies. Many smaller competitors operate only under 503A. The 503B registration signals a larger production scale and more rigorous quality controls, though it does not equal FDA drug approval.

PCAB Accreditation

Help holds accreditation from the Pharmacy Compounding Accreditation Board (PCAB), which is administered by the Accreditation Commission for Health Care (ACHC). PCAB accreditation requires on-site surveys, review of standard operating procedures, and demonstration of USP <797> (sterile) and USP <795> (non-sterile) compliance. Accreditation is voluntary, so holding it does differentiate Help from unaccredited compounders, though patients should still request certificates of analysis (COAs) for any compounded product they receive.

Help Pharmacy's Product Portfolio

Help compounds across several hormone and metabolic categories. The breadth of this catalog is one reason the pharmacy has become a preferred fulfillment partner for many telehealth platforms.

Compounded GLP-1 Agonists

Compounded semaglutide and tirzepatide have been Help's highest-profile products since 2023. FDA placed branded semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) on its drug shortage list, which temporarily allowed 503A and 503B compounders to produce these molecules legally [2]. Compounded GLP-1s from Help are typically supplied as multi-dose vials for subcutaneous injection rather than the single-use auto-injector pens sold by Eli Lilly and Novo Nordisk.

Several clinical points are worth stating clearly:

• Compounded semaglutide is the base molecule (semaglutide free acid or semaglutide sodium), not the same salt form as Wegovy or Ozempic (semaglutide sodium with specific inactive excipients). The FDA has noted this distinction in its guidance [2].
• Clinical trial data on compounded formulations does not exist. The weight-loss evidence base (for example, the STEP-1 trial, N=1,961, showing 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg vs. 2.4% with placebo, P<0.001) [3] applies to the branded, FDA-approved product, not to compounded versions.
• In February 2025, FDA determined that the shortage of tirzepatide had been resolved and issued guidance that 503B facilities could no longer compound tirzepatide under shortage provisions. Semaglutide shortage status has also been contested; patients should confirm current legal availability with their prescriber at the time of ordering.

Hormone Replacement Therapy

Help compounds bioidentical estradiol, progesterone, and testosterone in multiple delivery forms: topical creams, sublingual troches, patches, pellets, and injections. The Endocrine Society's 2023 clinical practice guideline on menopause acknowledges that compounded bioidentical hormones (cBHT) are widely used but notes that "FDA-approved hormone therapies have demonstrated efficacy and safety profiles that compounded products cannot claim" [4]. That is a real limitation patients deserve to know.

Testosterone cypionate for males (TRT) is another high-volume Help product. Standard dosing for hypogonadism ranges from 50 to 200 mg per week via injection, and Help compounds both standard concentrations and custom concentrations not available commercially [5].

Peptides and Specialty Formulations

Help compounds peptides including sermorelin, ipamorelin, BPC-157, and PT-141, among others. Many peptides lack FDA approval as drugs; their compounding legality is nuanced and jurisdiction-specific. Sermorelin (growth-hormone-releasing hormone analog) is an FDA-approved drug with an established compounding history. BPC-157 and several other peptides are classified by the FDA as "bulk drug substances that may not be used in compounding" under certain lists, so availability changes as FDA guidance evolves [6]. Prescribers and patients should verify the current FDA bulk drug substance list before ordering.

Is Help Pharmacy Legitimate? Regulatory Track Record

Help holds a valid Texas state pharmacy license, a PCAB accreditation, and 503B FDA registration. By those objective markers, it meets the baseline legal requirements to operate. Legitimacy, however, is not a permanent binary status for any compounding pharmacy.

FDA Inspection History

The FDA inspects 503B outsourcing facilities and posts Warning Letters publicly. As of the date of this article's last review, Help has not received an active FDA Warning Letter. Patients can verify this by searching the FDA's Warning Letter database at fda.gov [7]. That record is worth checking periodically, because Warning Letters can be issued at any time if inspection findings reveal manufacturing deviations.

What "Legitimate" Does Not Guarantee

Even a fully licensed, PCAB-accredited pharmacy produces drugs that are not FDA-approved. The FDA's own language is direct: "Compounded drugs do not have FDA approval. This means FDA has not verified their safety, effectiveness, or quality." [2] For patients who cannot access or afford branded GLP-1 medications, a well-credentialed compounding pharmacy like Help may represent a reasonable option decided upon in consultation with a physician. That decision should be made with clear eyes, not marketing assumptions.

Help Pharmacy Pricing and Business Model

Help does not sell directly to patients through a consumer website the way a retail pharmacy does. Its model is business-to-prescriber. Physicians, clinics, and telehealth platforms place accounts with Help and order on behalf of their patients.

Typical Cost Ranges

The HealthRX clinical team compiled the following typical price ranges based on publicly disclosed partner clinic pricing as of early 2025. These are patient-facing prices set by the ordering provider, not Help's wholesale rates, which are not publicly disclosed.

| Product | Typical Patient-Facing Monthly Cost | |---|---| | Compounded semaglutide (maintenance dose, ~1 mg/week) | $150 to $350/month | | Compounded tirzepatide (when available, ~5-10 mg/week) | $250 to $500/month | | Compounded estradiol cream (standard cycle) | $40 to $120/month | | Testosterone cypionate (TRT, 100 mg/week) | $50 to $150/month | | Sermorelin/ipamorelin combination | $150 to $300/month |

For comparison, branded Wegovy without insurance carries a list price of approximately $1,349 per month as of 2025. Branded Zepbound lists at approximately $1,059 per month. The cost gap between compounded and branded GLP-1s is substantial, and it is the primary commercial driver of the compounding pharmacy sector's growth [8].

The Telehealth Partnership Model

Help's practical reach is multiplied by partnerships with telehealth providers. A patient using a GLP-1 telehealth platform (such as Henry Meds, Mochi Health, or a direct-pay weight-loss clinic) may never know that Help is their fulfillment pharmacy. The prescriber selects Help from their approved pharmacy list, and the medication ships directly to the patient. This means patient reviews of those telehealth services often reflect Help's product and shipping quality indirectly. It also means that patient experience can vary based on the telehealth platform's prescribing protocols, not just Help's compounding practices.

Help Pharmacy vs. Alternatives

Several compounding pharmacies operate in the same space. The most commonly compared alternatives include Tailor Made Compounding, Belmar Pharmacy, and Olympia Pharmacy for HRT and peptides, and Strive Pharmacy or ProMedica for GLP-1 compounds.

Key Differentiators to Evaluate

A patient or prescriber comparing pharmacies should assess:

1. 503A vs. 503B status. Only a 503B facility faces FDA manufacturing-level oversight. Help holds both designations.
2. PCAB accreditation. Not all competitors hold this.
3. Certificate of analysis access. A reputable compounder provides COAs from third-party analytical labs for each batch, verifying potency and sterility.
4. Shipping footprint. Not every compounder ships to every state. Some peptides or hormone formulations face state-specific restrictions.
5. Prescriber network. If your telehealth provider only works with one pharmacy, your choice is effectively made for you.

Help's scale is a double-edged factor. Large batch production can improve consistency. It can also mean that individual patient needs receive less customization than a smaller 503A shop might offer.

Clinical Considerations for Prescribers and Patients

Prescribers recommending Help products should document several things in the clinical record. The rationale for compounding over the branded equivalent, the patient's informed consent acknowledging the non-FDA-approved status of the product, and any allergy or tolerance considerations driving the specific formulation choice. The American Society of Health-System Pharmacists provides guidance on appropriate clinical use of compounded preparations [9].

GLP-1 Monitoring Regardless of Formulation

Whether a patient uses branded or compounded semaglutide, the monitoring parameters do not change. The American Diabetes Association's 2024 Standards of Care recommend assessing weight, glycemic markers, and GI tolerability at 4-week intervals during dose titration [10]. Starting doses of semaglutide for obesity typically follow a titration from 0.25 mg per week, advancing to the target dose over 16 to 20 weeks to reduce nausea and vomiting.

HRT: Matching the Evidence Base

The Menopause Society (formerly NAMS) states in its 2023 position statement that "FDA-approved hormone therapy remains the preferred option when appropriate" and that cBHT "should be reserved for patients with documented need for a non-commercially available dose or delivery route." [11] Help's HRT catalog can serve that patient subgroup appropriately when that specific clinical rationale exists.

Patient Experience: What Reviews Reveal

Aggregated patient reviews of Help Pharmacy (primarily collected through Google Business and telehealth partner platforms) generally cite fast shipping (2 to 5 business days), adequate packaging for temperature-sensitive products, and correct fill accuracy. Negative reports cluster around two themes: occasional backorder delays during high-demand periods (particularly for compounded semaglutide in 2023 and early 2024) and difficulty reaching customer support directly, since most patient interactions are routed through the ordering prescriber rather than through Help itself.

These experiential data points are consistent with the pharmacy's B2B model. Help is not structured for direct patient support in the way a retail pharmacy is. Patients who want to track an order or ask a clinical question typically must go through their prescriber's office or telehealth platform.

Regulatory Outlook: What May Change

The FDA's evolving position on compounded GLP-1 drugs is the biggest near-term risk factor for Help's highest-revenue product line. Once FDA formally removes semaglutide from the drug shortage list, 503B facilities lose their legal basis to compound it in bulk. The FDA issued a draft guidance in January 2025 indicating its intent to remove semaglutide from the shortage list, though legal challenges from compounding industry groups were pending as of this article's last review [2].

If that removal becomes final and survives legal challenge, Help's compounded semaglutide business would need to shift to 503A patient-specific compounding (requiring documented clinical rationale for each prescription) or cease. Patients and prescribers relying on compounded semaglutide should monitor FDA announcements and have a contingency plan, such as pursuing manufacturer patient assistance programs for branded Wegovy or Zepbound.